CoChat
Sign Up
Cited by 110Estrogen and related hormone effectsProstate Cancer Treatment and ResearchBreast Cancer Treatment Studies

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.

Bentel, Jacqueline M, Birrell, Stephen N, Pickering, Marie A, Holds, Duncan J, Horsfall, David J, Tilley, Wayne D·1999·Molecular and Cellular Endocrinology
DOI 10.1016/s0303-7207(99)00109-4
Open this paper in CoChat — free account

Abstract

Medroxyprogesterone acetate (MPA), which is frequently used as second line hormonal therapy for the treatment of metastatic breast cancer, binds with high affinity to the progesterone receptor (PR). However, the androgenic side-effects of MPA suggest that it may also activate androgen receptor (AR) regulated pathways. Treatment of the human breast cancer cell lines MDA-MB-453, ZR-75-1 and T47-D with high dose (100 nM) MPA resulted in 26-30% inhibition of cell growth, which was partially reversed by co-treatment with a 10-fold excess of the synthetic antiandrogen, anandron. Scatchard analysis demonstrated specific, high affinity (non-PR) binding of [3H]MPA to cytosols prepared from the PR-/AR+ MDA-MB-453 and PR+/AR+ ZR-75-1, but not the PR-/AR- BT-20 breast cancer cell lines. Competition of [3H]MPA binding to MDA-MB-453 cytosols by equimolar concentrations of androgens (5alpha-dihydrotestosterone (DHT), R1881) and the antiandrogen, anandron was consistent with binding of MPA to the AR. In ZR-75-1 cell cytosol fractions, DHT, R1881 and anandron only partially competed out [3H]MPA binding, suggesting that androgens displace [3H]MPA binding to AR but not to PR. Induction by MPA of AR transactivation was demonstrated in MDA-MB-453 and ZR-75-1 cells, and in the CV-1 cell line transfected with a full-length AR. In these cell lines the increased activity of the androgen responsive reporter gene (MMTV-CAT) by 1 nM MPA was fully (MDA-MB-453, CV-1) or partially (ZR-75-1) inhibited by co-culture with 1 microM anandron. These findings indicate that MPA is an AR agonist and suggest that the in vivo effects of MPA in breast cancer patients may in part be mediated by the AR.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0303-7207(99)00109-4

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 110

Related

See all

Metadata

Authors
Bentel, J. M., Birrell, S. N., Pickering, M. A., Holds, D. J., Horsfall, D. J., & Tilley, W. D.
Affiliations
  • Royal Perth Hospital (AU)
  • Flinders University (AU)
Corresponding author
Tilley, Wayne D
ORCID
Venue
Molecular and Cellular Endocrinology
Publisher
Elsevier BV
Published
1999-08
Volume
154
Issue
1-2
Pages
11-20
ISSN
0303-7207 (ISSN-L)
DOI
10.1016/s0303-7207(99)00109-4
OpenAlex
W1971344086
Cited by
110
References
40
Citations by year
2026: 2 · 2025: 2 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 3 · 2017: 3 · 2016: 3 · 2015: 6 · 2014: 4 · 2013: 9 · 2012: 7
FWCI
2.64
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Molecular and Cellular Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Flinders Medical Centre Foundation
  • Ramaciotti Foundations
  • National Health and Medical Research Council
  • National Medical Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
medroxyprogesterone acetate, androgen receptor, androgen receptor agonists, breast cancer, progesterone receptor, androgen receptor antagonists, androgen receptor transactivation, MDA-MB-453, ZR-75-1, BT-20, androgen binding, hormonal therapy side effects
MeSH terms
Androgen Antagonists, Androgens, Antineoplastic Agents, Binding, Competitive, Breast Neoplasms, Cell Division, Cytosol, Female, Gene Expression Regulation, Humans, Imidazoles, Progestins, Receptors, Androgen, Transcription, Genetic, Tritium, Tumor Cells, Cultured, Medroxyprogesterone Acetate, Imidazolidines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review